Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 949068, 6 pages
http://dx.doi.org/10.1155/2014/949068
Clinical Study

Evaluating the Efficacy of Primary Treatment for Graves’ Disease Complicated by Thyrotoxic Periodic Paralysis

1Department of Surgery, The University of Hong Kong, Hong Kong
2Division of Endocrine Surgery, Department of Surgery, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong

Received 16 February 2014; Revised 22 June 2014; Accepted 14 July 2014; Published 3 August 2014

Academic Editor: Andreas Tomaschitz

Copyright © 2014 Rita Yuk-Kwan Chang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Chan, R. Shinde, C. C. Chow, C. S. Cockram, and R. Swaminathan, “In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis,” British Medical Journal, vol. 303, no. 6810, pp. 1096–1099, 1991. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Chaudhury, F. Ismail-Beigi, G. G. Gick, R. Levenson, and I. S. Edelman, “Effect of thyroid hormone on the abundance of Na,K-adenosine triphosphatase alpha-subunit messenger ribonucleic acid,” Molecular Endocrinology, vol. 1, no. 1, pp. 83–89, 1987. View at Publisher · View at Google Scholar · View at Scopus
  3. A. J. McFadzean and R. Yeung, “Periodic paralysis complicating thyrotoxicosis in Chinese.,” The British Medical Journal, vol. 1, no. 538, pp. 451–455, 1967. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Okinaka, K. Shizume, S. Lino et al., “The association of periodic paralysis and hyperthyroidism in Japan,” The Journal of Clinical Endocrinology and Metabolism, vol. 17, no. 12, pp. 1454–1459, 1957. View at Publisher · View at Google Scholar · View at Scopus
  5. K. P. Ober, “Thyrotoxic periodic paralysis in the United States: report of 7 cases and review of the literature,” Medicine, vol. 71, no. 3, pp. 109–120, 1992. View at Google Scholar · View at Scopus
  6. A. W. C. Kung, “Clinical Review: thyrotoxic periodic paralysis: a diagnostic challenge,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 7, pp. 2490–2495, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Ahmed and S. S. Chilimuri, “Fatal dysrhythmia following potassium replacement for hypokalemic periodic paralysis,” The Western Journal of Emergency Medicine, vol. 11, no. 1, pp. 57–59, 2010. View at Google Scholar
  8. R. T. T. Yeung and T. F. Tse, “Thyrotoxic periodic paralysis: effect of propranolol,” The American Journal of Medicine, vol. 57, no. 4, pp. 584–590, 1974. View at Publisher · View at Google Scholar · View at Scopus
  9. R. S. Bahn, H. B. Burch, D. S. Cooper et al., “Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,” Thyroid, vol. 21, no. 6, pp. 593–646, 2011. View at Google Scholar
  10. J. Yip, B. H. Lang, and C. Lo, “Changing trend in surgical indication and management for Graves' disease,” The American Journal of Surgery, vol. 203, no. 2, pp. 162–167, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. D. S. Cooper, “Antithyroid drugs,” The New England Journal of Medicine, vol. 352, no. 9, pp. 905–917, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Mazza, M. Carlini, D. Flecchia et al., “Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study,” Journal of Endocrinological Investigation, vol. 31, no. 10, pp. 866–872, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. C. C. Chang, C. J. Cheng, C. C. Sung et al., “A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: focus on symptomatology and precipitants,” European Journal of Endocrinology, vol. 169, no. 5, pp. 529–536, 2013. View at Publisher · View at Google Scholar
  14. V. Sundaresh, J. P. Brito, and L. Z. Wang, “Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 9, pp. 3671–3677, 2013. View at Google Scholar
  15. S. E. Van Hofe, S. G. Dorfman, R. F. Carretta, and R. L. Young, “The increasing incidence of hypothyroidism within one year after radioiodine therapy for toxic diffuse goiter,” Journal of Nuclear Medicine, vol. 19, no. 2, pp. 180–184, 1978. View at Google Scholar · View at Scopus
  16. F. Bogazzi, C. Giovannetti, R. Fessehatsion et al., “Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 1, pp. 201–208, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Metso, P. Jaatinen, H. Huhtala, T. Luukkaala, H. Oksala, and J. Salmi, “Long-term follow-up study of radioiodine treatment of hyperthyroidism,” Clinical Endocrinology, vol. 61, no. 5, pp. 641–648, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Akar, A. Comlekci, M. Birlik et al., “Thyrotoxic periodic paralysis in a turkish male; the recurrence of the attack after radioiodine treatment,” Endocrine Journal, vol. 52, no. 1, pp. 149–151, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Wong and B. H. Lang, “Graves' ophthalmopathy as an indication increased the risk of hypoparathyroidism after bilateral thyroidectomy,” World Journal of Surgery, vol. 35, no. 10, pp. 2212–2218, 2011. View at Publisher · View at Google Scholar · View at Scopus